Patents by Inventor Martin Bryant
Martin Bryant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8931394Abstract: Apparatuses and methods for facilitating reloading and resisting recoil of a firearm include an elastic member in communication with a portion of the firearm. A contact member coupled to the portion of the firearm, the elastic member, or combinations thereof, is movable between a first position in which movement of the portion of the firearm is biased by the elastic member and a second position in which movement of the portion of the firearm is generally unaffected by the elastic member. An actuator can be used to move the contact member between the first and second positions.Type: GrantFiled: October 31, 2011Date of Patent: January 13, 2015Inventors: Martin Bryant, James M. Buschow
-
Publication number: 20120308602Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: ApplicationFiled: June 5, 2012Publication date: December 6, 2012Applicant: MedImmune, LLCInventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant, David Kirkwood Clarke, Peter Palese
-
Patent number: 8297176Abstract: An improved semiautomatic firearm is provided comprising as assembly which reduces the effort of cocking the firearm or loading a first cartridge. A spring tube contains an inner recoil spring which is employed only during cycling of the firearm when firing. For initial cocking purposes, the inner recoil spring is bypassed in favor of a lighter outer spring which is selectively engaged by the user. When the inner recoil spring is engaged, both inner and outer springs are employed without adversely affecting the recoil dynamics of the firearm.Type: GrantFiled: February 23, 2011Date of Patent: October 30, 2012Inventors: James M. Buschow, Martin Bryant
-
Publication number: 20120167425Abstract: An improved semiautomatic firearm is provided comprising as assembly which reduces the effort of cocking the firearm or loading a first cartridge. A spring tube contains an inner recoil spring which is employed only during cycling of the firearm when firing. For initial cocking purposes, the inner recoil spring is bypassed in favor of a lighter outer spring which is selectively engaged by the user. When the inner recoil spring is engaged, both inner and outer springs are employed without adversely affecting the recoil dynamics of the firearm.Type: ApplicationFiled: February 23, 2011Publication date: July 5, 2012Inventors: James M. Buschow, Martin Bryant
-
Publication number: 20120048104Abstract: Apparatuses and methods for facilitating reloading and resisting recoil of a firearm include an elastic member in communication with a portion of the firearm. A contact member coupled to the portion of the firearm, the elastic member, or combinations thereof, is movable between a first position in which movement of the portion of the firearm is biased by the elastic member and a second position in which movement of the portion of the firearm is generally unaffected by the elastic member. An actuator can be used to move the contact member between the first and second positions.Type: ApplicationFiled: October 31, 2011Publication date: March 1, 2012Inventors: Martin Bryant, James M. Buschow
-
Publication number: 20110045023Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: ApplicationFiled: August 13, 2010Publication date: February 24, 2011Applicant: MEDIMMUNE,LLCInventors: HONG JIN, RODERICK TANG, SHENGQIANG LI, MARTIN BRYANT, DAVID KIRKWOOD CLARKE, PETER PALESE
-
Publication number: 20100028377Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: ApplicationFiled: May 4, 2009Publication date: February 4, 2010Applicant: MEDIMMUNE, LLCInventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant, David Kirkwood Clarke, Peter Palese
-
Publication number: 20090274727Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: ApplicationFiled: May 4, 2009Publication date: November 5, 2009Applicant: MEDIMMUNE, LLCInventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Publication number: 20090175899Abstract: The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present invention, the recombinant RS viral vectors and viruses are engineered to contain heterologous genes, including genes of other viruses, pathogens, cellular genes, tumor antigens, or to encode combinations of genes from different strains of RSV.Type: ApplicationFiled: November 7, 2008Publication date: July 9, 2009Applicant: MEDIMMUNE, LLCInventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Patent number: 7465574Abstract: The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present invention, the recombinant RS viral vectors and viruses are engineered to contain heterologous genes, including genes of other viruses, pathogens, cellular genes, tumor antigens, or to encode combinations of genes from different strains of RSV.Type: GrantFiled: March 11, 2005Date of Patent: December 16, 2008Assignee: MedImmune, LLCInventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Publication number: 20080279892Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: ApplicationFiled: March 26, 2007Publication date: November 13, 2008Applicant: MedImmune Vaccines, Inc.Inventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Publication number: 20080064655Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-axyl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: ApplicationFiled: October 30, 2007Publication date: March 13, 2008Applicants: Indenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, L'Universite Montpellier IIInventors: Gilles Gosselin, Jean-Louis Imbach, Martin Bryant
-
Publication number: 20070087995Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?-deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: ApplicationFiled: November 9, 2006Publication date: April 19, 2007Applicants: Idenix Pharmaceuticals, Inc., Centre National de La Recherche Sceintifique, L'Universite Montpellier IIInventors: Gilles Gosselin, Jean-Louis Imbach, Martin Bryant
-
Patent number: 7205013Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: GrantFiled: October 25, 2004Date of Patent: April 17, 2007Assignee: MedImmune Vaccines, Inc.Inventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Publication number: 20060264468Abstract: N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents.Type: ApplicationFiled: June 22, 2006Publication date: November 23, 2006Inventors: Richard Mueller, Martin Bryant, Richard Partis
-
Publication number: 20060240410Abstract: The present invention is directed to a method for the treatment of mammalian retrovirus infections, such as HIV, using combinations of retroviral protease inhibitors which are effective in preventing the replication of the retroviruses in vitro or in vivo. This invention, in particular, relates to protease inhibitor compounds used in combination therapy with other protease inhibitor compounds. This invention also relates to combination therapy with a combination of protease inhibitors and antiviral agents other than protease inhibitors.Type: ApplicationFiled: April 4, 2006Publication date: October 26, 2006Applicant: G.D. Searle & Co.Inventors: Martin Bryant, Karen Potts, Mary Smidt, Simon Tucker
-
Publication number: 20060106044Abstract: A method for inhibiting sexual transmission of HIV comprising topically applying to the skin or epithelial tissue of a human a composition comprising a non-nucleoside reverse transcriptase inhibitor (“NNRTI”) that is able to inhibit viral replication for periods exceeding 12, 24, or even 36 days, at concentrations below even 10 uM. In one embodiment the NNRTI is a dihydro-alkyloxy-benzyl-oxopyrimidine (DABO).Type: ApplicationFiled: January 5, 2006Publication date: May 18, 2006Applicant: Idenix Pharmaceuticals Inc.Inventors: Jean-Pierre Sommadossi, Paolo Colla, Marino Artico, Martin Bryant
-
Publication number: 20060084624Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?-deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-eythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: ApplicationFiled: September 22, 2005Publication date: April 20, 2006Applicant: Idenix Pharmaceuticals Inc.Inventors: Gilles Gosselin, Jean-Louis Imbach, Martin Bryant
-
Publication number: 20060025375Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2?-deoxy-?-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2?-deoxy-?-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2?-deoxy-?-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.Type: ApplicationFiled: September 20, 2005Publication date: February 2, 2006Applicant: Idenix Pharmaceuticals Inc.Inventors: Gilles Gosselin, Jean-Louis Imbach, Martin Bryant
-
Publication number: 20050267153Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.Type: ApplicationFiled: August 3, 2004Publication date: December 1, 2005Inventors: Richard Mueller, Martin Bryant, Richard Partis, Gary Jacob, Timothy Block, Raymond Dwek